Compare CVS Health Corp (CVS) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs PubMatic Inc — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while PubMatic Inc trades at $18.56 (market cap $845.86M). The key difference: CVS Health Corp is far larger — about 133× PubMatic Inc's market cap, and CVS Health Corp pays a 3.02% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and PubMatic Inc for 40 Days on average.
| CVS | PUBM | |
|---|---|---|
Market Cap | $112.49B | $845.86M |
Volume | 8,467,392 | 519,667 |
Sector | Health | Technology |
52-Week High | $110.60 | $19.18 |
52-Week Low | $70.08 | $6.28 |
Typical Hold Time | 83 Days | 40 Days |
Enterprise Value | $174.83B | $748.99M |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
PubMatic (PUBM) trades at $18.68, up 1.8% with bullish technical signals and strong analyst support. The stock shows positive momentum with recent earnings beats and double-digit revenue growth in Q2 2026. Despite negative net margins, the company maintains robust gross margins of 64.43% and positive operating cash flow of $81.06M in 2025. Recent leadership appointments and AI product launches signal strategic growth initiatives.
The outlook remains cautiously optimistic with Wall Street consensus at Buy (64.7%) and $19.89 price target. Key risks include persistent profitability challenges and competitive pressures in digital advertising. The stock's elevated P/E of 132 reflects growth expectations but requires sustained execution to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
